Which of the following agents are classified as reversible AChE inhibitors for Alzheimer's disease?

The classification of reversible acetylcholinesterase (AChE) inhibitors is crucial in the treatment of Alzheimer's disease, as these medications work by increasing the levels of acetylcholine in the brain, thereby enhancing cholinergic transmission, which is often impaired in Alzheimer's patients.

The correct choice includes Galantamine, Donepezil, and Rivastigmine. Each of these agents is specifically designed and approved for treating Alzheimer's disease by temporarily inhibiting the action of acetylcholinesterase, the enzyme responsible for breaking down acetylcholine. By doing this, they help sustain acetylcholine's effect on neuronal receptors, which can lead to improved cognitive function and management of dementia symptoms.

Galantamine not only inhibits AChE but also modulates nicotinic receptors, contributing to its cognitive benefits. Donepezil is well-established for its effectiveness and is often used as a first-line treatment option for Alzheimer's. Rivastigmine, which is available in both oral and transdermal forms, is significant for its ease of use and effectiveness in managing symptoms.

In contrast, while other choices may include compounds that affect cholinergic activity, they do not all meet the criteria strictly as reversible AChE inhibitors specific to Alzheimer's treatment. For